阅读说明：本技术 来源于微球菌属细菌的纳米囊泡及其用途 (Nanocysomes derived from Micrococcus bacteria and uses thereof ) 是由 金润根 于 2019-02-27 设计创作，主要内容包括：本发明涉及来源于微球菌属细菌的囊泡及其用途。本发明的发明人已经通过实验证实,与正常人相比,在患有胃癌、胰腺癌、胆管癌、乳腺癌、卵巢癌、膀胱癌、心肌梗塞、心肌病、房颤、变异型心绞痛、慢性阻塞性肺病(COPD)、痴呆和糖尿病的患者的样品中的囊泡显著减少,并且当注射从菌株中分离的囊泡时,显著抑制了由病原囊泡(如来源于大肠杆菌的囊泡)引起的炎性介质的分泌。因此,根据本发明,来源于微球菌属细菌的囊泡可有效地用于开发诊断胃癌、胰腺癌、胆管癌、乳腺癌、卵巢癌、膀胱癌、心肌梗塞、心肌病、房颤、变异型心绞痛、COPD、痴呆或糖尿病的方法,以及用于预防、减轻或治疗该疾病的组合物的目的。(The present invention relates to vesicles derived from bacteria of the genus Micrococcus and uses thereof. The inventors of the present invention have experimentally confirmed that vesicles in samples of patients with gastric cancer, pancreatic cancer, cholangiocarcinoma, breast cancer, ovarian cancer, bladder cancer, myocardial infarction, cardiomyopathy, atrial fibrillation, variant angina, Chronic Obstructive Pulmonary Disease (COPD), dementia, and diabetes are significantly reduced compared to normal persons, and secretion of inflammatory mediators caused by pathogenic vesicles such as those derived from escherichia coli is significantly inhibited when vesicles isolated from strains are injected. Therefore, according to the present invention, vesicles derived from micrococcus bacteria can be effectively used for the purpose of developing a method for diagnosing stomach cancer, pancreatic cancer, cholangiocarcinoma, breast cancer, ovarian cancer, bladder cancer, myocardial infarction, cardiomyopathy, atrial fibrillation, variant angina pectoris, COPD, dementia, or diabetes, and a composition for preventing, alleviating, or treating the disease.)

1. A method of providing information for diagnosing stomach cancer, pancreatic cancer, cholangiocarcinoma, breast cancer, ovarian cancer, bladder cancer, myocardial infarction, cardiomyopathy, atrial fibrillation, variant angina, Chronic Obstructive Pulmonary Disease (COPD), dementia, or diabetes, the method comprising the steps of:

(a) extracting DNA from extracellular vesicles isolated from a sample of a normal individual and a sample of a subject;

(b) performing Polymerase Chain Reaction (PCR) on the extracted DNA using paired primers prepared based on a gene sequence present in 16S rDNA to obtain each PCR product; and

(c) the cases in which the content of extracellular vesicles derived from the bacteria belonging to the genus Micrococcus is lower than that of the normal individual sample are classified into gastric cancer, pancreatic cancer, cholangiocarcinoma, breast cancer, ovarian cancer, bladder cancer, myocardial infarction, cardiomyopathy, atrial fibrillation, variant angina pectoris, Chronic Obstructive Pulmonary Disease (COPD), dementia, or diabetes by quantitative analysis of the PCR product.

2. The method of claim 1, wherein the sample in step (a) is blood.

3. A pharmaceutical composition for preventing or treating one or more diseases selected from the group consisting of gastric cancer, pancreatic cancer, cholangiocarcinoma, breast cancer, ovarian cancer, bladder cancer, myocardial infarction, cardiomyopathy, atrial fibrillation, variant angina pectoris, atopic dermatitis, psoriasis, acne vulgaris, alopecia, macular degeneration, Chronic Obstructive Pulmonary Disease (COPD), dementia, and diabetes, which comprises vesicles derived from a bacterium belonging to the genus micrococcus as an active ingredient.

4. The pharmaceutical composition of claim 3, wherein the average diameter of the vesicles is from 10 to 200 nm.

5. The pharmaceutical composition of claim 3, wherein the vesicle is naturally or artificially secreted from a bacterium belonging to the genus Micrococcus.

6. The pharmaceutical composition according to claim 3, wherein the vesicle derived from a bacterium belonging to the genus Micrococcus is a vesicle derived from Micrococcus luteus.

7. A food composition for preventing or alleviating one or more diseases selected from the group consisting of gastric cancer, pancreatic cancer, cholangiocarcinoma, breast cancer, ovarian cancer, bladder cancer, myocardial infarction, cardiomyopathy, atrial fibrillation, variant angina pectoris, atopic dermatitis, psoriasis, acne vulgaris, alopecia, macular degeneration, Chronic Obstructive Pulmonary Disease (COPD), dementia, and diabetes, comprising vesicles derived from a bacterium belonging to the genus micrococcus as an active ingredient.

8. The food composition of claim 7, wherein the average diameter of the vesicles is from 10 to 200 nm.

9. The food composition of claim 7, wherein the vesicles are naturally or artificially secreted from a bacterium belonging to the genus Micrococcus.

10. Food composition according to claim 7, wherein the vesicles derived from bacteria belonging to the genus Micrococcus are vesicles derived from Micrococcus luteus.

11. An inhalation composition for preventing or treating one or more diseases selected from the group consisting of gastric cancer, pancreatic cancer, cholangiocarcinoma, breast cancer, ovarian cancer, bladder cancer, myocardial infarction, cardiomyopathy, atrial fibrillation, variant angina pectoris, atopic dermatitis, psoriasis, acne vulgaris, alopecia, macular degeneration, Chronic Obstructive Pulmonary Disease (COPD), dementia, and diabetes, comprising vesicles derived from a bacterium belonging to the genus micrococcus as an active ingredient.

12. A cosmetic composition for preventing or alleviating one or more diseases selected from the group consisting of atopic dermatitis, psoriasis, acne vulgaris and alopecia, comprising vesicles derived from a bacterium belonging to the genus Micrococcus as an active ingredient.

13. A method of diagnosing gastric cancer, pancreatic cancer, cholangiocarcinoma, breast cancer, ovarian cancer, bladder cancer, myocardial infarction, cardiomyopathy, atrial fibrillation, variant angina, Chronic Obstructive Pulmonary Disease (COPD), dementia, or diabetes, the method comprising the steps of:

(a) extracting DNA from extracellular vesicles isolated from a sample of a normal individual and a sample of a subject;

(b) performing Polymerase Chain Reaction (PCR) on the extracted DNA using paired primers prepared based on a gene sequence present in 16S rDNA to obtain each PCR product; and

(c) the case in which the content of extracellular vesicles derived from the bacterium belonging to the genus Micrococcus is lower than that of the normal individual sample is determined as gastric cancer, pancreatic cancer, cholangiocarcinoma, breast cancer, ovarian cancer, bladder cancer, myocardial infarction, cardiomyopathy, atrial fibrillation, variant angina pectoris, Chronic Obstructive Pulmonary Disease (COPD), dementia, or diabetes by quantitative analysis of the PCR product.

14. A method for preventing or treating one or more diseases selected from the group consisting of gastric cancer, pancreatic cancer, cholangiocarcinoma, breast cancer, ovarian cancer, bladder cancer, myocardial infarction, cardiomyopathy, atrial fibrillation, variant angina, atopic dermatitis, psoriasis, acne vulgaris, alopecia, macular degeneration, Chronic Obstructive Pulmonary Disease (COPD), dementia, and diabetes, the method comprising the steps of: administering to the subject a pharmaceutical composition comprising as an active ingredient vesicles derived from a bacterium belonging to the genus Micrococcus.

15. Use of vesicles derived from a bacterium belonging to the genus Micrococcus for the prevention or treatment of one or more diseases selected from the group consisting of gastric cancer, pancreatic cancer, bile duct cancer, breast cancer, ovarian cancer, bladder cancer, myocardial infarction, cardiomyopathy, atrial fibrillation, variant angina pectoris, atopic dermatitis, psoriasis, acne vulgaris, alopecia, macular degeneration, Chronic Obstructive Pulmonary Disease (COPD), dementia, and diabetes.

Technical Field

The present invention relates to nanovesicles derived from bacteria belonging to the genus Micrococcus (genus Micrococcus) and uses thereof, and more particularly, to a method of diagnosing gastric cancer, pancreatic cancer, cholangiocarcinoma, breast cancer, ovarian cancer, bladder cancer, myocardial infarction, cardiomyopathy, atrial fibrillation, variant angina pectoris, Chronic Obstructive Pulmonary Disease (COPD), dementia, or diabetes, etc., by using nanovesicles derived from bacteria belonging to the genus Micrococcus, and a composition for preventing, alleviating, or treating the disease including the nanovesicles.

Background

Since the beginning of the 21 st century, acute infectious diseases, which have been considered epidemic diseases in the past, have become less important, and chronic diseases accompanied by immune dysfunction due to disharmony between human and microbiome have changed disease patterns, becoming major diseases that determine quality of life and human longevity. As intractable chronic diseases in the 21 st century, cancer, cardiovascular diseases, chronic pulmonary diseases, metabolic diseases, and neuropsychiatric diseases have become important problems of national public health, and have become major diseases that determine the life span and quality of life of human beings. These intractable chronic diseases are characterized by chronic inflammation accompanied by immune dysfunction caused by pathogenic agents.

As is well known, the number of coexisting microorganisms in the human body has reached 100 trillion, which is 10 times of the number of human cells, and the number of microbial genes is more than 100 times of the number of human genes. A microbiota or group of microorganisms refers to a community of microorganisms, including bacteria, archaea, and eukaryotes present in a given habitat.

Bacteria that coexist in our body and bacteria present in the surrounding environment secrete nano-sized vesicles in order to exchange information on genes, low-molecular compounds, proteins, and the like with other cells. The mucosa forms a physical defense membrane through which particles having a size of 200 nanometers (nm) or more cannot pass, and thus bacteria coexisting in the mucosa cannot pass, but vesicles derived from the bacteria have a size of 100 nm or less and are relatively freely passed through epithelial cells through the mucosa and then absorbed into our body. Vesicles derived from bacteria, which are locally secreted by bacteria, are absorbed through mucosal epithelial cells to cause local inflammatory reactions, while vesicles passing through epithelial cells are absorbed through lymphatic system to be distributed in various organs, and immune and inflammatory reactions are regulated in the organs where the vesicles are distributed.

For example, vesicles derived from pathogenic gram-negative bacteria (e.g., escherichia coli) locally induce colitis upon transvascular absorption and promote systemic inflammatory responses and coagulation through vascular endothelial inflammatory responses. In addition, these vesicles are absorbed into muscle cells and the like on which insulin acts to cause insulin resistance and diabetes. In contrast, vesicles derived from beneficial bacteria can modulate disease by modulating immune and metabolic dysfunction caused by pathogenic vesicles.

As an immune response to factors such as vesicles derived from bacteria, a Th17 immune response characterized by secretion of Interleukin (IL) -17 cytokine occurs, in which IL-6 is secreted when exposed to vesicles derived from bacteria, thereby inducing a Th17 immune response. Inflammation caused by Th17 immune response is characterized by neutrophil infiltration, and during inflammation, tumor necrosis factor-alpha (TNF-alpha) secreted from inflammatory cells such as macrophages and the like plays an important role in the development of disease.

Bacteria belonging to the genus Micrococcus, which are gram-positive bacteria belonging to the family Micrococcaceae, are widely distributed in nature, for example, in water, dust, soil, and the like. Among them, Micrococcus luteus (Micrococcus luteus) is known to produce riboflavin when grown in toxic organic pollutants such as pyridine and to absorb ultraviolet rays through lutein pigment. It is also known that bacteria belonging to the genus Micrococcus are isolated from dairy products and beer and grown in a dry or high-salt environment, and the bacteria survive for a long time at a refrigerating temperature in a refrigerator although spores are not formed. However, the secretion of vesicles extracellularly by bacteria belonging to the genus Micrococcus has not been reported, and particularly, the use thereof for the diagnosis and treatment of cancer, cardiovascular diseases, allergic/chronic pulmonary diseases, dementia, or metabolic diseases has not been reported.

Disclosure of Invention

[ problem ] to provide a method for producing a semiconductor device

In order to solve the above-mentioned problems, the inventors of the present invention have conducted intensive studies and confirmed that the content of vesicles derived from bacteria belonging to the genus micrococcus is significantly reduced in a sample derived from a patient suffering from gastric cancer, pancreatic cancer, cholangiocarcinoma, breast cancer, ovarian cancer, bladder cancer, myocardial infarction, cardiomyopathy, atrial fibrillation, variant angina, Chronic Obstructive Pulmonary Disease (COPD), dementia, or diabetes, as compared to normal persons, through metagenomic analysis. It was also confirmed that when vesicles are isolated from Micrococcus luteus, which is a bacterium belonging to the genus Micrococcus, and macrophages are treated therewith, secretion of IL-6 and TNF- α by pathogenic vesicles is significantly inhibited, and the present invention has been completed based on these findings.

Accordingly, it is an object of the present invention to provide a method for providing information for diagnosing gastric cancer, pancreatic cancer, bile duct cancer, breast cancer, ovarian cancer, bladder cancer, myocardial infarction, cardiomyopathy, atrial fibrillation, variant angina pectoris, Chronic Obstructive Pulmonary Disease (COPD), dementia, or diabetes,

further, it is another object of the present invention to provide a composition for preventing, alleviating or treating gastric cancer, pancreatic cancer, cholangiocarcinoma, breast cancer, ovarian cancer, bladder cancer, myocardial infarction, cardiomyopathy, atrial fibrillation, variant angina pectoris, atopic dermatitis, psoriasis, acne vulgaris, alopecia, macular degeneration, Chronic Obstructive Pulmonary Disease (COPD), dementia and diabetes, which comprises vesicles derived from a bacterium belonging to the genus micrococcus as an active ingredient.

However, the technical problems to be achieved by the present invention are not limited to the above-mentioned problems, and other problems not mentioned may be clearly understood by those skilled in the art from the following description.

[ technical solution ] A

In order to achieve the above object of the present invention, the present invention provides a method of providing information for diagnosing stomach cancer, pancreatic cancer, cholangiocarcinoma, breast cancer, ovarian cancer, bladder cancer, myocardial infarction, cardiomyopathy, atrial fibrillation, variant angina pectoris, Chronic Obstructive Pulmonary Disease (COPD), dementia, or diabetes, the method including the steps of:

(a) extracting DNA from extracellular vesicles isolated from a sample of a normal individual and a sample of a subject;

(b) performing Polymerase Chain Reaction (PCR) on the extracted DNA using paired primers prepared based on a gene sequence present in 16S rDNA to obtain each PCR product; and

(c) the cases in which the content of extracellular vesicles derived from the bacteria belonging to the genus Micrococcus is lower than that of the normal individual sample are classified into gastric cancer, pancreatic cancer, cholangiocarcinoma, breast cancer, ovarian cancer, bladder cancer, myocardial infarction, cardiomyopathy, atrial fibrillation, variant angina pectoris, Chronic Obstructive Pulmonary Disease (COPD), dementia, or diabetes by quantitative analysis of the PCR product.

In addition, the present invention provides a method for diagnosing gastric cancer, pancreatic cancer, bile duct cancer, breast cancer, ovarian cancer, bladder cancer, myocardial infarction, cardiomyopathy, atrial fibrillation, variant angina pectoris, Chronic Obstructive Pulmonary Disease (COPD), dementia, or diabetes, which comprises the steps of:

(a) extracting DNA from extracellular vesicles isolated from a sample of a normal individual and a sample of a subject;

(b) performing Polymerase Chain Reaction (PCR) on the extracted DNA using paired primers prepared based on a gene sequence present in 16S rDNA to obtain each PCR product; and

(c) the case in which the content of extracellular vesicles derived from the bacterium belonging to the genus Micrococcus is lower than that of the normal individual sample is determined as gastric cancer, pancreatic cancer, cholangiocarcinoma, breast cancer, ovarian cancer, bladder cancer, myocardial infarction, cardiomyopathy, atrial fibrillation, variant angina pectoris, Chronic Obstructive Pulmonary Disease (COPD), dementia, or diabetes by quantitative analysis of the PCR product.

As an exemplary embodiment of the present invention, the sample in step (a) may be blood.

As another exemplary embodiment of the present invention, the pair of primers in step (b) may be primers of SEQ ID Nos. 1 and 2.

Further, the present invention provides a pharmaceutical composition for preventing or treating gastric cancer, pancreatic cancer, bile duct cancer, breast cancer, ovarian cancer, bladder cancer, myocardial infarction, cardiomyopathy, atrial fibrillation, variant angina pectoris, atopic dermatitis, psoriasis, acne vulgaris, alopecia, macular degeneration, Chronic Obstructive Pulmonary Disease (COPD), dementia, or diabetes, comprising vesicles derived from a bacterium belonging to the genus micrococcus as an active ingredient.

In one embodiment of the present invention, the pharmaceutical composition may comprise an ophthalmic composition.

In addition, the present invention provides a food composition for preventing or alleviating gastric cancer, pancreatic cancer, bile duct cancer, breast cancer, ovarian cancer, bladder cancer, myocardial infarction, cardiomyopathy, atrial fibrillation, variant angina pectoris, atopic dermatitis, psoriasis, acne vulgaris, alopecia, macular degeneration, Chronic Obstructive Pulmonary Disease (COPD), dementia, or diabetes, comprising vesicles derived from a bacterium belonging to the genus micrococcus as an active ingredient.

In addition, the present invention provides an inhalation composition for preventing or treating gastric cancer, pancreatic cancer, bile duct cancer, breast cancer, ovarian cancer, bladder cancer, myocardial infarction, cardiomyopathy, atrial fibrillation, variant angina pectoris, atopic dermatitis, psoriasis, acne vulgaris, alopecia, macular degeneration, Chronic Obstructive Pulmonary Disease (COPD), dementia, or diabetes, comprising vesicles derived from a bacterium belonging to the genus micrococcus as an active ingredient.

In addition, the present invention provides a cosmetic composition for preventing or reducing atopic dermatitis, psoriasis, acne vulgaris or alopecia, comprising vesicles derived from a bacterium belonging to the genus Micrococcus as an active ingredient.

In addition, the present invention provides a method for preventing or treating gastric cancer, pancreatic cancer, bile duct cancer, breast cancer, ovarian cancer, bladder cancer, myocardial infarction, cardiomyopathy, atrial fibrillation, variant angina pectoris, atopic dermatitis, psoriasis, acne vulgaris, alopecia, macular degeneration, Chronic Obstructive Pulmonary Disease (COPD), dementia, or diabetes, the method comprising the steps of: administering to the subject a pharmaceutical composition comprising as an active ingredient vesicles derived from a bacterium belonging to the genus Micrococcus.

Further, the present invention provides use of vesicles derived from a bacterium belonging to the genus Micrococcus for preventing or treating gastric cancer, pancreatic cancer, cholangiocarcinoma, breast cancer, ovarian cancer, bladder cancer, myocardial infarction, cardiomyopathy, atrial fibrillation, variant angina pectoris, atopic dermatitis, psoriasis, acne vulgaris, alopecia, macular degeneration, Chronic Obstructive Pulmonary Disease (COPD), dementia, or diabetes.

As still another exemplary embodiment of the present invention, the average diameter of the vesicle may be 10 to 200 nm.

As another exemplary embodiment of the present invention, the vesicle may be naturally or artificially secreted from a bacterium belonging to the genus micrococcus.

As another exemplary embodiment of the present invention, the vesicle derived from a bacterium belonging to the genus micrococcus may be a vesicle derived from micrococcus luteus.

[ PROBLEMS ] the present invention

The present inventors confirmed that enteric bacteria are not absorbed into the body, but vesicles derived from bacteria are absorbed into the body through epithelial cells, distributed systemically, and excreted from the body through the kidneys, liver, and lungs, and confirmed that vesicles derived from bacteria present in the blood of patients through macrogenomic analysis are significantly reduced in vesicles derived from bacteria belonging to the genus micrococcus present in the blood of patients with gastric cancer, pancreatic cancer, bile duct cancer, breast cancer, ovarian cancer, bladder cancer, myocardial infarction, cardiomyopathy, atrial fibrillation, variant angina, Chronic Obstructive Pulmonary Disease (COPD), dementia, and diabetes, as compared to that in normal humans. It was also confirmed that when micrococcus luteus, which is a bacterium belonging to the genus Micrococcus, is cultured in vitro and vesicles are isolated therefrom, and then the isolated vesicles are administered to inflammatory cells in vitro, secretion of inflammatory mediators by the pathogenic vesicles is significantly inhibited, and thus, it is expected that the vesicles derived from the bacterium belonging to the genus Micrococcus can be effectively used in a method for diagnosing stomach cancer, pancreatic cancer, bile duct cancer, breast cancer, ovarian cancer, bladder cancer, myocardial infarction, cardiomyopathy, atrial fibrillation, variant angina, Chronic Obstructive Pulmonary Disease (COPD), dementia or diabetes, and a composition for preventing, alleviating or treating the above diseases, and the like.

Drawings

Fig. 1A is a series of photographs of distribution patterns of bacteria and bacteria-derived vesicles (EV) captured by time after oral administration of the bacteria and the bacteria-derived vesicles (EV) to mice, and fig. 1B is a result of evaluating the in vivo distribution patterns of the bacteria and the vesicles by collecting blood, kidneys, liver, and various organs 12 hours after oral administration of the bacteria and the vesicles.

Fig. 2 is a result of comparing the distribution of vesicles derived from bacteria belonging to the genus micrococcus after metagenomic analysis of vesicles derived from bacteria present in blood of gastric cancer patients and normal individuals.

FIG. 3 is a result of comparing the distribution of vesicles derived from bacteria belonging to the genus Micrococcus after metagenomic analysis of vesicles derived from bacteria present in blood of pancreatic cancer patients and normal individuals.

Fig. 4 is a result of comparing the distribution of vesicles derived from bacteria belonging to the genus micrococcus after metagenomic analysis of vesicles derived from bacteria present in blood of bile duct cancer patients and normal individuals.

Fig. 5 is a result of comparing the distribution of vesicles derived from bacteria belonging to the genus micrococcus after metagenomic analysis of vesicles derived from bacteria present in blood of breast cancer patients and normal individuals.

Fig. 6 is a result of comparing the distribution of vesicles derived from bacteria belonging to the genus micrococcus after metagenomic analysis of vesicles derived from bacteria present in blood of ovarian cancer patients and normal individuals.

Fig. 7 is a result of comparing the distribution of vesicles derived from bacteria belonging to the genus micrococcus after metagenomic analysis of vesicles derived from bacteria present in blood of bladder cancer patients and normal individuals.

FIG. 8 is a result of comparing the distribution of vesicles derived from bacteria belonging to the genus Micrococcus after metagenomic analysis of vesicles derived from bacteria present in blood of patients with myocardial infarction and normal individuals.

Fig. 9 is a result of comparing the distribution of vesicles derived from bacteria belonging to the genus micrococcus after metagenomic analysis of vesicles derived from bacteria present in blood of patients with cardiomyopathy and normal individuals.

Fig. 10 is a result of comparing the distribution of vesicles derived from bacteria belonging to the genus micrococcus after metagenomic analysis of vesicles derived from bacteria present in blood of patients with atrial fibrillation and normal individuals.

Fig. 11 is a result of comparing the distribution of vesicles derived from bacteria belonging to the genus micrococcus after metagenomic analysis of vesicles derived from bacteria present in blood of patients with variant angina pectoris and normal individuals.

Fig. 12 is a result of comparing the distribution of vesicles derived from bacteria belonging to the genus micrococcus after metagenomic analysis of vesicles derived from bacteria present in blood of Chronic Obstructive Pulmonary Disease (COPD) patients and normal individuals.

Fig. 13 is a result of comparing the distribution of vesicles derived from bacteria belonging to the genus micrococcus after metagenomic analysis of vesicles derived from bacteria present in blood of dementia patients and normal individuals.

Fig. 14 is a result of comparing the distribution of vesicles derived from bacteria belonging to the genus micrococcus after metagenomic analysis of vesicles derived from bacteria present in blood of diabetic patients and normal individuals.

FIG. 15 shows the results of comparing the degree of secretion of IL-6 and TNF- α (which are inflammatory mediators) between macrophages (Raw264.7 cells) treated with vesicles derived from Micrococcus luteus and Escherichia coli EV (which are pathogenic vesicles) to evaluate the effect of vesicles derived from Micrococcus luteus on the induction of inflammation.

FIG. 16 shows the results of evaluating the effect of vesicles derived from Micrococcus luteus on the secretion of IL-6 and TNF- α as inflammatory mediators caused by E.coli EV after pretreatment with the vesicles and then treatment with E.coli EV, which is a pathogenic vesicle, to evaluate the effect of vesicles derived from Micrococcus luteus on anti-inflammation and immunomodulation.

Detailed Description

The present invention relates to vesicles derived from bacteria belonging to the genus Micrococcus and uses thereof.

The inventors of the present invention confirmed by metagenomic analysis that the content of vesicles derived from bacteria belonging to the genus micrococcus was significantly reduced in clinical samples derived from patients with gastric cancer, pancreatic cancer, cholangiocarcinoma, breast cancer, ovarian cancer, bladder cancer, myocardial infarction, cardiomyopathy, atrial fibrillation, variant angina pectoris, Chronic Obstructive Pulmonary Disease (COPD), dementia, and diabetes, as compared to normal individuals, and thus confirmed that these diseases could be diagnosed. In addition, by isolating vesicles from Micrococcus luteus and analyzing the properties thereof, it was confirmed that the vesicles can be used as a composition for preventing, alleviating or treating, for example, gastric cancer, pancreatic cancer, cholangiocarcinoma, breast cancer, ovarian cancer, bladder cancer, myocardial infarction, cardiomyopathy, atrial fibrillation, variant angina, atopic dermatitis, macular degeneration, Chronic Obstructive Pulmonary Disease (COPD), dementia, and diabetes, and the like.

Accordingly, the present invention provides a method of providing information for diagnosing gastric cancer, pancreatic cancer, bile duct cancer, breast cancer, ovarian cancer, bladder cancer, myocardial infarction, cardiomyopathy, atrial fibrillation, variant angina pectoris, Chronic Obstructive Pulmonary Disease (COPD), dementia, or diabetes, the method including the steps of:

(a) extracting DNA from extracellular vesicles isolated from a sample of a normal individual and a sample of a subject;

(b) performing Polymerase Chain Reaction (PCR) on the extracted DNA using paired primers prepared based on a gene sequence present in 16S rDNA to obtain each PCR product; and

(c) the case in which the content of extracellular vesicles derived from the bacterium belonging to the genus Micrococcus is lower than that of the normal individual sample is determined as gastric cancer, pancreatic cancer, cholangiocarcinoma, breast cancer, ovarian cancer, bladder cancer, myocardial infarction, cardiomyopathy, atrial fibrillation, variant angina pectoris, Chronic Obstructive Pulmonary Disease (COPD), dementia, or diabetes by quantitative analysis of the PCR product.

As used herein, the term "diagnosis" refers to the determination of a disease condition of a patient in a broad sense and in all aspects. The determination is made as to the entity, cause, pathogenesis, severity, detailed aspect of the disease, presence or absence of complications, prognosis, etc. of the disease. The diagnosis in the present invention refers to determination of occurrence or non-occurrence of gastric cancer, pancreatic cancer, cholangiocarcinoma, breast cancer, ovarian cancer, bladder cancer, myocardial infarction, cardiomyopathy, atrial fibrillation, variant angina pectoris, Chronic Obstructive Pulmonary Disease (COPD), dementia, and/or diabetes, degree of disease, and the like.

As used herein, the term "nanovesicle" or "vesicle" refers to a structure composed of nano-sized membranes secreted from various bacteria.

Vesicles or Outer Membrane Vesicles (OMVs) derived from gram-negative bacteria have not only endotoxins (lipopolysaccharides) but also toxic proteins and bacterial DNA and RNA, and vesicles derived from gram-positive bacteria have peptidoglycans and lipoteichoic acids, which are cell wall components of bacteria, in addition to proteins and nucleic acids. In the present invention, the nanovesicles or vesicles are naturally secreted or artificially produced by bacteria of the genus Micrococcus, are spherical in shape, and have an average diameter of 10 to 200 nm.

As used herein, the term "metagenome" also refers to microbiome, and refers to the entire genome including all viruses, bacteria, fungi, etc., in independent areas such as soil and animal intestines, and is generally used as a concept of genome explaining analysis of uncultured microorganisms by identifying a large number of microorganisms at a time using a sequence analyzer. In particular, metagenome does not refer to the genome of one species, but refers to a mixed genome, the genome of all species as one environmental unit. When a species is defined in the course of the development of omics biology, the metagenome is a term derived from the point of view of forming a complete species, formed by various species interacting with each other as well as a functionally present species. Technically, metagenome is the target of a technology that recognizes all species in one environment by analyzing all DNA and RNA through a rapid sequence analysis method, and studies interaction and metabolism regardless of species.

In the present invention, the sample may be blood, but is not limited thereto.

As another aspect of the present invention, the present invention provides a composition for preventing, treating or alleviating gastric cancer, pancreatic cancer, cholangiocarcinoma, breast cancer, ovarian cancer, bladder cancer, myocardial infarction, cardiomyopathy, atrial fibrillation, variant angina pectoris, atopic dermatitis, psoriasis, acne vulgaris, alopecia, macular degeneration, Chronic Obstructive Pulmonary Disease (COPD), dementia or diabetes, comprising vesicles derived from a bacterium belonging to the genus micrococcus as an active ingredient. The composition includes food compositions, inhalant compositions, cosmetic compositions and pharmaceutical compositions.

In addition, in the present invention, the food composition includes a health functional food composition, and the pharmaceutical composition may include an ophthalmic composition, but the present invention is not limited thereto.

As used herein, the term "preventing" refers to all actions of inhibiting gastric cancer, pancreatic cancer, bile duct cancer, breast cancer, ovarian cancer, bladder cancer, myocardial infarction, cardiomyopathy, atrial fibrillation, variant angina, atopic dermatitis, psoriasis, acne vulgaris, alopecia, macular degeneration, Chronic Obstructive Pulmonary Disease (COPD), dementia, and/or diabetes, etc., or delaying the onset thereof by administering a composition according to the present invention.

As used herein, the term "treatment" refers to all behaviors that reduce or beneficially alter the symptoms of gastric cancer, pancreatic cancer, cholangiocarcinoma, breast cancer, ovarian cancer, bladder cancer, myocardial infarction, cardiomyopathy, atrial fibrillation, variant angina, atopic dermatitis, psoriasis, acne vulgaris, alopecia, macular degeneration, Chronic Obstructive Pulmonary Disease (COPD), dementia, or diabetes, etc., by administering a composition according to the present invention.

As used herein, the term "alleviating" refers to all actions that at least reduce a parameter (e.g., the extent of symptoms) associated with the condition being treated.

The vesicles may be separated from the culture solution containing the bacteria belonging to the genus Micrococcus by using one or more methods selected from centrifugation, ultracentrifugation, high-pressure treatment, extrusion, sonication, cell lysis, homogenization, freeze-thawing, electroporation, mechanical disintegration, chemical treatment, filtration through a filter, gel filtration chromatography, free-flow electrophoresis, and capillary electrophoresis. In addition, processes such as washing for removing impurities and concentrating the obtained vesicles may be further included.

The pharmaceutical compositions of the present invention may comprise a pharmaceutically acceptable carrier. Pharmaceutically acceptable carriers are generally used in the formulation, and include, but are not limited to, physiological saline (saline), sterile water, ringer's solution, buffered saline, cyclodextrin, glucose solution, maltodextrin solution, glycerol, ethanol, liposomes, and the like, and may further include other typical additives such as antioxidants and buffers, if necessary. In addition, the composition may be formulated into injectable preparations such as aqueous solutions, suspensions and emulsions, pills, capsules, granules or tablets by additionally adding diluents, dispersants, surfactants, binders, lubricants and the like. With respect to suitable pharmaceutically acceptable carriers and formulations, the compositions may preferably be formulated according to each ingredient by using the methods disclosed in Remington's decoction (the ramington literature). The formulation of the pharmaceutical composition of the present invention is not particularly limited, but may be formulated into injections, inhalants, external preparations for skin, oral preparations, and the like.

The pharmaceutical composition of the present invention may be orally administered or parenterally administered (e.g., intravenously, subcutaneously, intradermally, intranasally or intratracheally administered) according to the target method, and the administration dose may vary according to the condition and body weight of a patient, the severity of a disease, the drug form and the administration route and cycle, but may be appropriately selected by one of ordinary skill in the art.

The pharmaceutical compositions of the present invention are administered in a pharmaceutically effective amount. In the present invention, a pharmaceutically effective amount means an amount sufficient to treat a disease at a reasonable benefit/risk ratio applicable to medical treatment, and an effective dosage level may be determined according to factors including: the type of disease in a patient, the severity of the disease, the activity of the drug, the sensitivity to the drug, the time of administration, the route of administration, the rate of excretion, the period of treatment and concomitant use of the drug, and other factors well known in the medical arts. The composition according to the present invention may be administered as a therapeutic agent alone or in combination with other therapeutic agents, may be administered sequentially or simultaneously with the therapeutic agents in the related art, and may be administered in a single dose or multiple doses. In view of all the above factors, it is important to administer the composition in the minimum amount that can achieve the maximum effect without any side effects, which can be readily determined by one of ordinary skill in the art.

Specifically, the effective amount of the pharmaceutical composition according to the present invention may vary depending on the age, sex and body weight of a patient, and is usually 0.001 to 150mg of the composition per 1 kg of body weight, preferably 0.01 to 100mg per 1 kg of body weight, and may be administered daily or every other day, or once to three times daily. However, since the effective amount may be increased or decreased depending on the administration route, the severity of obesity, sex, body weight, age, etc., the administration dose is not intended to limit the scope of the present invention in any way.

In the inhalation composition of the present invention, the active ingredient may be directly added to the inhalant, or may be used in combination with other ingredients, and may be suitably used according to a conventional method. The mixing amount of the active ingredient may be appropriately determined depending on the purpose of its use (for prophylaxis or treatment).

The food composition of the present invention includes a health functional food composition. The food composition according to the present invention may be used by adding the active ingredient to food as it is, or may be used together with other food or food ingredients, but may be used as appropriate according to typical methods. The mixing amount of the active ingredient may be appropriately determined depending on the purpose of its use (for prevention or alleviation). Generally, when preparing a food or beverage, the composition of the present invention is added in an amount of 15% by weight or less, preferably 10% by weight or less, based on the raw materials.

Other ingredients are not particularly limited except that the food composition of the present invention contains the active ingredient in a designated ratio as an essential ingredient, and the food composition of the present invention may contain various flavors, natural carbohydrates, etc. as additional ingredients, like typical beverages. Examples of the above natural carbohydrates include conventional sugars such as monosaccharides such as glucose, fructose and the like; disaccharides such as maltose, sucrose, and the like; and polysaccharides such as dextrin, cyclodextrin and the like; and sugar alcohols such as xylitol, sorbitol and erythritol. As a flavoring agent other than the above-described flavoring agents, natural flavoring agents (thaumatin, stevia extracts such as rebaudioside a, glycyrrhizin, etc.) and synthetic flavoring agents (saccharin, aspartame, etc.) can be advantageously used.

In addition to the additives, the food composition of the present invention may contain various nutrients, vitamins, minerals (electrolytes), flavoring agents (e.g., synthetic flavoring agents and natural flavoring agents), coloring agents and fillers (cheese, chocolate, etc.), pectic acid and its salts, alginic acid and its salts, organic acids, protective colloid thickeners, pH adjusters, stabilizers, preservatives, glycerin, alcohols, carbonating agents used in carbonated beverages, and the like. These ingredients may be used alone or in combination thereof. The proportion of these additives may also be appropriately selected by those of ordinary skill in the art.

The cosmetic composition of the present invention may include not only vesicles derived from bacteria belonging to the genus Micrococcus but also ingredients commonly used in cosmetic compositions, and may include, for example, general adjuvants such as antioxidants, stabilizers, solubilizers, vitamins, pigments, and herbs, and carriers.

In addition, the composition of the present invention may contain, in addition to the vesicles derived from the micrococcus bacteria, a mixture of organic uv blockers for a long period of time in a range that does not adversely affect the skin-protecting effect by reacting with the vesicles derived from the micrococcus bacteria. The organic UV blocker may be selected from the group consisting of glyceryl PABA, cresyl troxazole trisiloxane (dihydrometrizole trisiloxane), cresyl troxazole (dihydrometrizole), trioleyl digallate (digalloyl triolate), disodium phenylbisbenzimidazole tetrasulfonate (discodium phenylbenzimidyl tetrasulfonate), diethylhexyl butamido triazone (diethylhexyl butamido triazoxide), diethylamino hydroxybenzoyl hexyl benzoate (diethylhexyl benzoylhexyl benzoate), DEA-methoxycinnamate (DEA-methoxycinnamyl), Lawson (Lawson) and dihydroxyacetone (dihydroxybenzoyl ketone) mixture, methylenebis-benzotriazolyl tetramethylbutylphenol (tolylene-tolylketone), 4-methylbenzylidene methyl benzoate (o-benzoylbenzophenone), o-benzophenon (o-benzoyloxy benzophenone-8-dihydroxybenzophenone) (benzophenone-tolyloxy-8-dihydroxybenzophenone (camphor-benzophenone), benzophenone-tolyloxy benzophenone (4-methylbenzylidene (benzal-8-benzophenone (camphor-benzophenone), benzophenone (tolyloxy-8-methoxybenzophenone (camphor-phenoxybenzophenone), benzophenone (tolyloxy) (benzophenone-phenoxybenzophenone-and benzophenone-and 4-and benzophenone (tolyloxy) (benzophenone-and 4-tolyloxy (tolyloxy) (benzophenone-and 4-and benzophenone-and a-, Butyl methoxydibenzoylmethane, bis ethylhexyloxyphenol methoxyphenyl triazine, cinnamate, ethyldihydroxypropyl PABA, octadiene, ethylhexyldimethyl PABA, ethylhexyl methoxycinnamate, ethylhexyl salicylate (ethylhexylsalicylate), ethylhexyltriazone (ethylhexyltriazine), isoamyl p-methoxycinnamate (isoamyl-p-methoxycinnamate), polysiloxane-15 (benzylidene malonate polysiloxane), poly silicon-15 (dimethylcinnamenyl maleate), p-xylylene dicamphor sulfonic acid (terephthallylidene dicamphor sulfonic acid) and salts thereof, TEA-salicylate, and p-aminobenzoic acid (PABA).

Examples of the products, to which the cosmetic composition of the present invention may be added, include cosmetics such as astringents, skin softeners, nourishing lotions, various creams, essences, masks (packs), foundations, and the like, cleansers, face washes, soaps, care agents, beauty lotions, and the like. Specific preparations of the cosmetic composition of the present invention include skin lotion, skin softener, skin toner, astringent, lotion, cream, moisturizing lotion, nourishing lotion, massage cream, nourishing cream, moisturizing cream, hand cream, essence, nourishing essence, mask, soap, shampoo, cleansing foam, cleansing lotion, cleansing cream, body lotion, body wash, milky lotion, lipstick, makeup base, foundation, pack, loose powder, eye shadow, and the like.

In one embodiment of the present invention, by orally administering bacteria and vesicles derived from bacteria to mice and observing the in vivo absorption, distribution and excretion patterns of the bacteria and vesicles, it was confirmed that, although bacteria are not absorbed through the intestinal mucosa, the vesicles derived from bacteria are absorbed and distributed systemically within 5 minutes after administration and are excreted through the kidney, liver, and the like (see example 1).

In another exemplary embodiment of the present invention, the bacterial metagenomic analysis is performed by using vesicles isolated from blood of normal individuals whose age and sex are matched with patients having gastric cancer, pancreatic cancer, bile duct cancer, breast cancer, ovarian cancer, bladder cancer, myocardial infarction, cardiomyopathy, atrial fibrillation, variant angina pectoris, Chronic Obstructive Pulmonary Disease (COPD), dementia, and diabetes. The results confirmed that vesicles derived from bacteria belonging to the genus micrococcus were significantly reduced in clinical samples of patients with gastric cancer, pancreatic cancer, bile duct cancer, breast cancer, ovarian cancer, bladder cancer, myocardial infarction, cardiomyopathy, atrial fibrillation, variant angina pectoris, Chronic Obstructive Pulmonary Disease (COPD), dementia, and diabetes, as compared with samples of normal individuals (see examples 3 to 15).

In another embodiment of the present invention, it was evaluated whether vesicles secreted from a cultured Micrococcus luteus strain exhibit immunomodulatory and anti-inflammatory effects, and it was confirmed that secretion of IL-6 and TNF- α by vesicles derived from Escherichia coli is effectively inhibited by vesicles derived from Micrococcus luteus by evaluating inflammatory mediators secreted from macrophages treated with vesicles derived from Micrococcus luteus at different concentrations and then treated with vesicles derived from Escherichia coli serving as causative agents of inflammatory diseases (see example 18).

Hereinafter, preferred embodiments will be presented to aid in understanding the present invention. However, the following examples are provided only for easier understanding of the present invention, and the contents of the present invention are not limited by the following examples.